Lacutamab

拉可妥单抗

Report date: 2025/11/10 17:18:43
First In Class

Base Information

Drug NameLacutamab
Drug Alias NamePH-41IPH-4102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionKiller cell immunoglobulin-like receptor 3DL2 antagonists
TargetsKiller cell immunoglobulin-like receptor 3DL2
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralSezary SyndromeMycosis Fungoides +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[11] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesInnate Pharma
China Registration ClassN/A

Develop Information

Active CompaniesInnate Pharma
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, PeripheralSezary SyndromeMycosis Fungoides +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A